cas 304445-49-6, 3-FLUORO-4-BROMO-ACETOPHENONE

Articles about 304445-49-6Total 12 be found

ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR
Disclosed are compounds inhibiting the conversion of α–KG to D-2-HG, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition c
-
Page/Page column 105; 106

(2021/04/17)

NOVEL BENZIMIDAMIDES COMPOUNDS COMPRISING AN OXABORININ RING
The invention relates to 4-(1-hydroxy-3,4-dihydro-1H-benzo[c][1,2]oxaborinin-3-yl)benzimidamide derivatives and their use in treating diseases and conditions of the skin (for example, Netherton syndrome, rosacea, atopic dermatitis, psoriasis and itch) cau
-
Page/Page column 38

(2019/12/28)

Synthesis method of 3-fluoro-4-bromo-acetophenone
The invention relates to a synthesis method of 3-fluoro-4-bromo-acetophenone. The method includes: taking 3-fluoro-4-bromo-benzoyl chloride, dimethylhydroxyamine hydrochloride and methylmagnesium chloride as the raw materials, carrying out aminolysis, ext
-
Paragraph 0025; 0026; 0027; 0032; 0033; 0034; 0039-0041

(2017/08/27)

HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS
A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.
-
Paragraph 0477; 0479

(2017/12/17)

NOVEL AROMATIC COMPOUND AND USE THEREOF
Provided is a compound showing a bone formation promoting action (and/or bone resorption suppressive action). A compound of the formula (I) or a pharmacologically acceptable salt: [wherein each substituent is as defined in the DESCRIPTION], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or To treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, Paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.
-
Paragraph 0718-0720; 0874-0876

(2016/08/17)

3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
-
(2014/09/29)

HEPATITIS C INHIBITOR COMPOUNDS
Compounds of Formula (I) and (II) wherein R1, R2, R3, R6, A and A' are defined herein. The compounds are useful as inhibitors of the function of NS5A protein encoded by HCV for the treatment of hepatitis C viral infection.
-
Page/Page column 24

(2012/05/04)

IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS
The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.
-
Page/Page column 8

(2011/09/20)

SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-b][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME
The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.
-
Page/Page column 19

(2009/12/05)

PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS
The invention relates to compounds of formula (I) processes for their preparation, their use as 5-lipoxygenase inhibitors and pharmaceutical compositions containing the same.
-
Page/Page column 104; 134-135

(2009/07/03)